Clarus · DIN 02257963 · 40 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Clarus · DIN 02257963
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-07-19
Health Canada: Marketed since 2010-03-01 · brand CLARUS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Clarus: Formulary list price $1.90 per unit (the source does not state the unit; exact figure $1.9003). What the ministry pays, not the patient.
Ministry pays: $1.9003 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02257963)
Source record
DIN 02257963: Clarus
Raw flags: sec3=Y
Item: 843600034; group id 864; item number 2090; lccId None; manufacturer id MYL
Source form: Cap; strength: 40mg
Recorded listing: General benefit
Source prices (unrounded): $1.9003; ministry $1.9003
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02257963
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74320
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Accutane · DIN 00582352 · $1.9003
Shortage status: resolved shortage (ended August 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02257963
Shortage record checked October 6, 2026